These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37755658)

  • 1. Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management.
    Anastasilaki E; Paccou J; Gkastaris K; Anastasilakis AD
    Hormones (Athens); 2023 Dec; 22(4):611-622. PubMed ID: 37755658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
    Hayakawa N; Suzuki A
    Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for glucocorticoid-induced osteoporosis.
    Chiodini I; Merlotti D; Falchetti A; Gennari L
    Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis.
    Hayes KN; Baschant U; Hauser B; Burden AM; Winter EM
    Front Endocrinol (Lausanne); 2021; 12():782118. PubMed ID: 34975756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis.
    Tanaka Y; Soen S; Hirata S; Okada Y; Fujiwara S; Tanaka I; Kitajima Y; Kubota T; Ebina K; Takashi Y; Inoue R; Yamauchi M; Okubo N; Ueno M; Ohata Y; Ito N; Ozono K; Nakayama H; Terauchi M; Tanaka S; Fukumoto S
    J Bone Miner Metab; 2024 Mar; 42(2):143-154. PubMed ID: 38538869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Glucocorticoid Induced Osteoporosis.
    Cho SK; Sung YK
    Endocrinol Metab (Seoul); 2021 Jun; 36(3):536-543. PubMed ID: 34107602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk and management of osteoporosis due to inhaled, epidural, intra-articular or topical glucocorticoids.
    Anastasilakis AD; Naciu AM; Yavropoulou MP; Paccou J
    Joint Bone Spine; 2023 Dec; 90(6):105604. PubMed ID: 37399940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.
    Gourlay M; Franceschini N; Sheyn Y
    Clin Rheumatol; 2007 Feb; 26(2):144-53. PubMed ID: 16670825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
    Tanaka I
    Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first.
    Lespessailles E; Chapurlat R
    Osteoporos Int; 2020 Oct; 31(10):1829-1834. PubMed ID: 32780152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and glucocorticoid-induced osteoporosis: cons.
    Lems WF; Saag K
    Endocrine; 2015 Aug; 49(3):628-34. PubMed ID: 26041376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
    Murphy DR; Smolen LJ; Klein TM; Klein RW
    BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis.
    Chiodini I; Falchetti A; Merlotti D; Eller Vainicher C; Gennari L
    Expert Rev Endocrinol Metab; 2020 Jul; 15(4):283-298. PubMed ID: 32584619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
    Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
    Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid induced osteoporosis.
    Hu K; Adachi JD
    Expert Rev Endocrinol Metab; 2019 Jul; 14(4):259-266. PubMed ID: 31094232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.
    Laurent MR; Goemaere S; Verroken C; Bergmann P; Body JJ; Bruyère O; Cavalier E; Rozenberg S; Lapauw B; Gielen E
    Front Endocrinol (Lausanne); 2022; 13():908727. PubMed ID: 35757436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
    Bultink IE; Baden M; Lems WF
    Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of glucocorticoid-induced osteoporosis.
    Rizzoli R; Adachi JD; Cooper C; Dere W; Devogelaer JP; Diez-Perez A; Kanis JA; Laslop A; Mitlak B; Papapoulos S; Ralston S; Reiter S; Werhya G; Reginster JY
    Calcif Tissue Int; 2012 Oct; 91(4):225-43. PubMed ID: 22878667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.
    Yu SF; Chen JF; Chen YC; Lai HM; Ko CH; Chiu WC; Su FM; Hsu CY; Su BY; Wu CH; Cheng TT
    Medicine (Baltimore); 2017 Feb; 96(5):e5959. PubMed ID: 28151883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.